<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000094" GROUP_ID="STROKE" ID="850499072911245399" MERGED_FROM="" MODIFIED="2010-08-31 15:14:34 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2010-08-31 15:14:34 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Gangliosides for acute ischaemic stroke</TITLE>
<CONTACT MODIFIED="2010-08-31 15:14:34 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="6181" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Livia</FIRST_NAME><LAST_NAME>Candelise</LAST_NAME><EMAIL_1>livia.candelise@unimi.it</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Neurologiche</DEPARTMENT><ORGANISATION>Universita degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena</ORGANISATION><CITY>Milano</CITY><ZIP>20122</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>02-5465819</PHONE_1><PHONE_2>02-55185553</PHONE_2><FAX_1>02-55190392</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-08-31 15:14:34 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="6181" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Livia</FIRST_NAME><LAST_NAME>Candelise</LAST_NAME><EMAIL_1>livia.candelise@unimi.it</EMAIL_1><ADDRESS><DEPARTMENT>Dipartimento di Scienze Neurologiche</DEPARTMENT><ORGANISATION>Universita degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena</ORGANISATION><CITY>Milano</CITY><ZIP>20122</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>02-5465819</PHONE_1><PHONE_2>02-55185553</PHONE_2><FAX_1>02-55190392</FAX_1></ADDRESS></PERSON><PERSON ID="16448" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alfonso</FIRST_NAME><LAST_NAME>Ciccone</LAST_NAME><POSITION>Consultant Neurologist</POSITION><EMAIL_1>alfonso.ciccone@ospedaleniguarda.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology and Stroke Unit</DEPARTMENT><ORGANISATION>Azienda Ospedaliera Niguarda Ca' Granda</ORGANISATION><ADDRESS_1>Piazza Ospedale Maggiore 3</ADDRESS_1><CITY>Milano</CITY><ZIP>20162</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 02 64442348</PHONE_1><PHONE_2>+39 02 64442791</PHONE_2><FAX_1>+39 02 64442819</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-08-31 14:09:34 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="16" MONTH="1" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="7" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="1997"/>
</DATES>
<WHATS_NEW MODIFIED="2010-08-31 14:09:42 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2010-08-31 14:09:21 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="30" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>The Cochrane Stroke Group Trials Register was last searched for this review on 27 July 2010. No new relevant trials were found. The Cochrane Stroke Group Editorial Board believes that it is very unlikely that there will be any further trials in this topic area.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-08-31 14:09:42 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-31 14:09:42 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="21" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-08-21 13:13:10 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="16" MONTH="1" YEAR="2002"/>
<DESCRIPTION>
<P>We obtained unpublished data on a previously excluded trial (Heiss 1989) that is now included in the review. We have also slightly modified the conclusions.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-21 13:53:15 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-08-21 13:15:36 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-08-21 13:15:34 +0100" MODIFIED_BY="Hazel Fraser">Gangliosides for acute ischaemic stroke</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-21 13:15:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is no evidence that treatment with ganglioside reduces disability after stroke. Drugs which can reduce disability in people who survive an acute stroke are needed. Gangliosides are a component of cells membranes and can protect neurons against injuries and enhance their growth. Ganglioside treatment has been tested in many clinical trials, mostly on patients with stroke. The results of these studies were inconclusive. This review shows that there is no evidence in favour of this treatment for patients with acute stroke. Gangliosides can rarely cause damage to nerves (acute neuropathy).</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-21 13:13:50 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND>
<P>Gangliosides may have a protective effect on the central and peripheral nervous systems. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-08-21 13:13:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>To assess the effect of exogenous gangliosides in acute ischaemic stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group trials register (last searched: May 2001) and contacted drug companies and main investigators of included trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised trials of gangliosides compared with placebo or standard treatment in people with definite or presumed ischaemic stroke. Trials were included if people were randomised within 15 days of symptom onset and if mortality data were available.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>One reviewer applied the inclusion criteria. Two reviewers independently extracted the data. Trial quality was assessed.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-21 13:13:50 +0100" MODIFIED_BY="Hazel Fraser">
<P>Twelve trials involving 2265 people were included. All the trials tested purified monosialoganglioside GM1. Only three trials described the randomisation procedure. Follow up was between 15 to 180 days. Death at the end of follow up showed no significant difference (odds ratio 0.91, 95% confidence interval 0.73 to 1.13). There was no difference shown between early (within 48 hours) and delayed treatment. For disability, three trials did not show any improvement in Barthel index score with gangliosides (weighted mean difference 2.1; 95% confidence interval -4.8 to 8.9). In two trials, eight patients experienced adverse effects that led to discontinuation of ganglioside treatment, seven had skin reactions and one developed Guillain-Barré syndrome.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There is not enough evidence to conclude that gangliosides are beneficial in acute stroke. Caution is warranted because of reports of sporadic cases of Guillain-Barré syndrome after ganglioside therapy.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-21 13:53:15 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2008-08-21 13:16:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>A number of experimental studies have reported that exogenous gangliosides enhance collateral neuronal sprouting and may exert a neuroprotective effect on the central and peripheral nervous systems (<LINK REF="REF-Leeden-1984" TYPE="REFERENCE">Leeden 1984</LINK>; <LINK REF="REF-Skaper-1985" TYPE="REFERENCE">Skaper 1985</LINK>; <LINK REF="REF-Favaron-1988" TYPE="REFERENCE">Favaron 1988</LINK>). On this basis gangliosides started to be used in peripheral neuropathy, amyotrophic lateral sclerosis and acute ischaemic stroke. Up to now, despite the considerable number of controlled clinical trials available and the more than 2000 patients involved in clinical experimentation, great uncertainty still persists about the efficacy of this treatment in acute stroke.</P>
<P>Thus a systematic review of controlled clinical trials appears necessary to evaluate the potential efficacy or inefficacy of gangliosides in patients with acute stroke. Although this disease is one of the major causes of mortality, no effective treatment, with the exception of thrombolysis for selected patients and aspirin, has yet been identified. It is therefore important to assess all the drugs, even those with limited efficacy, that alone or in combination might be able to reduce case fatality and disability.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-08-21 13:15:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>To conduct a systematic review of clinical trials on gangliosides in acute stroke patients to evaluate whether:</P>
<P>(1) such treatments are significantly effective in reducing case fatality (primary objective);<BR/>(2) they are effective in reducing disability in surviving patients;<BR/>(3) they are safe enough for general use.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-21 13:53:15 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-08-21 13:16:18 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>All randomised controlled trials of a ganglioside(s) in acute ischaemic stroke were considered. We aimed to exclude trials in which allocation to treatment or control group was not concealed; however, we also included trials in which the method of allocation was not clearly described and we did not know if they were truly randomised.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with definite or presumed ischaemic stroke, in the acute phase, who started treatment no later than 15 days after symptom onset. Trials without pre-randomisation CT-scan were also included as about 80% of strokes are presumed to be ischaemic.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>All types of gangliosides (GM1, GD1a, GD1b, etc.), independently of duration, dosage and route of administration, were accepted for the treatment group. For the control group we accepted the use of placebo as well as standard therapy or other experimental treatments. To avoid confounded trials we excluded studies in which other experimental treatments were not the same in the ganglioside and the control group.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-21 13:16:18 +0100" MODIFIED_BY="Hazel Fraser">
<UL>
<LI>Number of deaths and/or number of dependent patients (unable to perform activities of daily living without help) at the end of the scheduled follow up.</LI>
<LI>Number of deaths within 30 days.</LI>
</UL>
<P>We accepted trials which reported only the case fatality rate even if information on disability was not given. Evaluation of neurological deterioration was not a major aim of this review. We extracted any available information about safety in both the ganglioside and control groups.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-21 13:52:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in May 2001. Personal inquiries were made to Fidia drug company for unpublished trials and missing data without obtaining any answer.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-21 13:53:15 +0100" MODIFIED_BY="Hazel Fraser">
<P>One of us (AC) selected trials for inclusion using the criteria outlined above. Before starting the analysis of the included studies we jointly reviewed the papers not meeting our inclusion criteria to reach agreement about their exclusion.</P>
<P>For each included trial we collected information on the method of randomisation, type of blinding procedure, and whether intention-to-treat analysis was performed. Balance between the two treatment groups for age and severity of neurological deficit was evaluated.</P>
<P>Baseline data on participants such as type of stroke, interval from onset of symptoms to randomisation and CT-scan, type and modalities of treatment, follow-up duration and outcome measures were also extracted from each paper.</P>
<P>The number of patients who died and remained disabled in the treated and control groups by the end of scheduled follow up was extracted by AC and LC separately. In case of discordance the papers were jointly reviewed to reach an agreement. We also extracted separately the number of patients excluded because they were withdrawn soon after randomisation as ineligible or later for various reasons or they dropped out during the follow up. For each excluded case we carefully sought any incidental follow up information on survival included in the papers, not only in the Results section. In the absence of such information, patients were defined by us as lost to follow up.</P>
<P>We conducted two separate analyses on case fatality. In the first, in accordance with the intention-to-treat method, we considered the number of all patients randomised per arm as the denominator and the number of deaths as the numerator of the case fatality rates assuming all the lost to follow up cases to be alive. In the second, a sensitivity analysis, we assumed all the patients lost to follow up to be dead and thus added them to the numerator of the case fatality rate in both the treatment and control groups, leaving the denominator unchanged.</P>
<P>Trials were subdivided according to the interval of time between stroke onset and randomisation. Thus, case fatality was evaluated in patients randomised within 5, 12, 48, and more than 48 hours after stroke.</P>
<P>With regard to disability, no studies reported categorical data for Barthel or Rankin scales, thus it was impossible to dichotomise the patients into dependent and independent categories at the end of scheduled follow up. We combined the mean score and standard deviation of the studies in which they were reported.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-21 13:26:32 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-08-21 13:23:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>Sixteen papers were selected (<LINK REF="STD-Bassi-1984" TYPE="STUDY">Bassi 1984</LINK>; <LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>; <LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>, <LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Jamieson-1989" TYPE="STUDY">Jamieson 1989</LINK>; <LINK REF="STD-Massarotti-1989" TYPE="STUDY">Massarotti 1989</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-Monaco-1991" TYPE="STUDY">Monaco 1991</LINK>; <LINK REF="STD-Papo-1991" TYPE="STUDY">Papo 1991</LINK>; <LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-Toso-1992" TYPE="STUDY">Toso 1992</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>; <LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>; <LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>) but only 12 were included. That of Papo (<LINK REF="STD-Papo-1991" TYPE="STUDY">Papo 1991</LINK>) was excluded because it concerned subarachnoid haemorrhage and those of Jamieson (<LINK REF="STD-Jamieson-1989" TYPE="STUDY">Jamieson 1989</LINK>), Massarotti (<LINK REF="STD-Massarotti-1989" TYPE="STUDY">Massarotti 1989</LINK>) and Toso (<LINK REF="STD-Toso-1992" TYPE="STUDY">Toso 1992</LINK>) because it was not possible to account for deaths and disability in the different allocation groups. The trials by Jamieson (<LINK REF="STD-Jamieson-1989" TYPE="STUDY">Jamieson 1989</LINK>), Monaco (<LINK REF="STD-Monaco-1991" TYPE="STUDY">Monaco 1991</LINK>) and Toso (<LINK REF="STD-Toso-1992" TYPE="STUDY">Toso 1992</LINK>) were identified only in abstract form and that of Massarotti (<LINK REF="STD-Massarotti-1989" TYPE="STUDY">Massarotti 1989</LINK>) in conference proceedings.</P>
<P>We sent to the main investigators of the 16 selected trials a questionnaire asking the following data: number of randomised patients; length of scheduled follow up; patients lost to follow up; patients dead at the end of the scheduled follow up; patients with severe disability (Rankin &gt; 2, Barthel &gt; 60) at the end of the scheduled follow-up period; mean Rankin and/or Barthel score and SD at the end of the scheduled follow up; number of patients who developed a Guillain-Barré syndrome or others major side effects. Five replied but only two (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>) added new useful data. The main characteristics of the studies are summarised in the tables (see "Characteristics of included/excluded studies").</P>
<P>The trials considered reflect very broad inclusion criteria and represent a heterogeneous group of patients in terms of type of stroke and treatment. EST (<LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>) included ischaemic stroke patients within five hours of symptoms onset, Monaco (<LINK REF="STD-Monaco-1991" TYPE="STUDY">Monaco 1991</LINK>) within 10 hours, Argentino (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>) within 12 hours and five other studies (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>; <LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>) randomised patients within 48 hours. In the other studies the interval of time between stroke and onset of treatment was longer than 48 hours (<LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>; <LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>). Six studies (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-Monaco-1991" TYPE="STUDY">Monaco 1991</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>; <LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>; <LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>) included only ischaemic stroke diagnosed by CT scan performed before randomisation. The proportion of haemorrhagic strokes in three studies in which CT-scan was performed after randomisation, was 8% (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>), 13% (<LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>) and 19% (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>). In two studies (<LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>) not all cases were evaluated with CT scan. In five studies (<LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>; <LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>) outcome data were not reported separately for ischaemic and haemorrhagic stroke and therefore we included the results for all patients together. Only patients with symptoms attributable to a hemispheric stroke were evaluated in six studies (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>; <LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>).</P>
<P>All the considered trials used the purified monosialoganglioside GM1. It was administered parenterally at a low dose (40 mg/day) in three studies (<LINK REF="STD-Bassi-1984" TYPE="STUDY">Bassi 1984</LINK>; <LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>); a dose of 100 mg/day or over was used in all other studies. In one study (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>) patients were randomised to four treatment groups: GM1, GM1 plus haemodilution, placebo, and placebo plus haemodilution. To avoid possible confounding effects we analysed separately GM1 versus placebo (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>) and GM1 plus haemodilution versus placebo plus haemodilution (<LINK REF="STD-Argentino-plus-haemo" TYPE="STUDY">Argentino plus haemo</LINK>). Also in Heiss study (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>) patients were randomised to GM1 plus haemodilution versus placebo plus haemodilution. In another trial (<LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>) vitamin PP, with unknown effect on stroke, was given as placebo. The duration of treatment was longer than 15 days in all the studies.</P>
<P>The authors themselves considered the case fatality rate as an outcome measure in five trials (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>). Disability was assessed with the Barthel (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>) or Rankin scale (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>). The neurological score with the Mathew (<LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-Bassi-1984" TYPE="STUDY">Bassi 1984</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>), Canadian (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-Monaco-1991" TYPE="STUDY">Monaco 1991</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>, <LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>) or other neurological scales (<LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>; <LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>; <LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>) was also used as an outcome measure in the papers analysed. The results for both disability and neurological deterioration were presented as mean score or mean score difference between the treatment and control group. They were never presented as categorical data except in one trial (<LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>). More detailed information on the disability and neurological deficit measures are presented in the table "Characteristics of Included Studies".</P>
<P>The length of scheduled follow up was 15 (<LINK REF="STD-Monaco-1991" TYPE="STUDY">Monaco 1991</LINK>), 30 (<LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>), 42 (<LINK REF="STD-Bassi-1984" TYPE="STUDY">Bassi 1984</LINK>; <LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>; <LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>), 84 (<LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>), 90 (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>), 120 (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>, <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>) and 180 (<LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>) days.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-21 13:24:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>The overall quality of the studies was good as regards both the double blind design, which was used in all except two studies (<LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>), and balance between treatment groups for age and neurological severity; only in one study (<LINK REF="STD-Bassi-1984" TYPE="STUDY">Bassi 1984</LINK>) was the mean age per group not specified. However, we found methodological shortcomings in the randomisation procedure and intention-to-treat analysis. The randomisation procedure was described in only three studies (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>) and in one of them (<LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>) was unclear. Only three trials were designed to perform an intention-to-treat analysis of which one (<LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>) considered only death as outcome measure and two both case fatality and neurological deterioration (<LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>; <LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>).</P>
<P>Withdrawals soon after randomisation were reported in all except three trials (<LINK REF="STD-Bassi-1984" TYPE="STUDY">Bassi 1984</LINK>; <LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>; <LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>). Kirczynska (<LINK REF="STD-Kirczynska-1994" TYPE="STUDY">Kirczynska 1994</LINK>) and Hoffbrand (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>) gave the number of withdrawals without specifying the treatment allocation group. Withdrawals and drop outs during follow up were described in all papers but one (<LINK REF="STD-Giraldi-1990" TYPE="STUDY">Giraldi 1990</LINK>). The percentage of excluded cases, withdrawals or drop outs, ranged from 0 (<LINK REF="STD-Wender-1993" TYPE="STUDY">Wender 1993</LINK>, personal communication) to 22% (<LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>). The number of patients lost to follow up as defined above in the Methods of the Review section was as follows: zero and one in the ganglioside and control groups in one trial (<LINK REF="STD-Monaco-1991" TYPE="STUDY">Monaco 1991</LINK>), four and one (<LINK REF="STD-Bassi-1984" TYPE="STUDY">Bassi 1984</LINK>), one and two (<LINK REF="STD-Battistin-1985" TYPE="STUDY">Battistin 1985</LINK>), two and two (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>), nine and six (<LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>), four and seven (<LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>), and none and five (<LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>), with the proportion ranging from 0.6% to 13%.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-21 13:26:32 +0100" MODIFIED_BY="Hazel Fraser">
<P>A total of 2265 cases were included, 1140 treated with GM1 and 1125 controls. The overall case fatality rate was 17%. The odds ratio (OR) for the treatment over the control group was 0.91 (95% confidence interval (CI) 0.71 to 1.13). The difference in favour of treatment was not statistically significant and there was no significant heterogeneity between trials (p = 0.5).</P>
<P>Classifying trials according to the interval of time between stroke onset and randomisation, OR were 1.07, 0.96, 0.75, 0.51 respectively for patients treated within five, 12, 48 and more than 48 hours. None of these differences reached statistical significance.</P>
<P>In the sensitivity analysis of case fatality we added 22 lost-to-follow-up cases in the GM1 group and 27 in the control group to the number of deaths in the numerator. The result again showed non significant results in favour of treatment (OR 0.89, 95% CI 0.72 to 1.10).</P>
<P>Exclusion of trials with possible confounding effect for the concomitant haemodilution treatment in the two group of randomisation (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Argentino-plus-haemo" TYPE="STUDY">Argentino plus haemo</LINK>) did not change the result.<BR/>
<BR/>When we considered disability, three small studies (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>) reported the mean Barthel index score and standard deviation in a total of 137 patients alive at the end of follow up. The pooled weighted mean score difference was 2.1 with wide 95% CI, from -4.8 to 8.9. There was significant heterogeneity between trials (p &lt; 0.00001), which disappears only if the Heiss study is removed.</P>
<P>With regard to safety, no major events were reported in most of the trials. Five patients in the SASS (<LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>) trial had a skin reaction severe enough to warrant discontinuation of the treatment. In the EST (<LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>) trial three patients experienced adverse events that led to permanent discontinuation of gangliosides, rash in two and an acute progressive polyradiculopathy consistent with Guillain-Barré&#8218; syndrome on day 10 after stroke in the third. However, the latter patient was alive and had improved at four months. In the Heiss study (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>) one patient developed an anaphylactic reaction (unpublished data).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-21 13:28:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>The results obtained with this systematic review are insufficient to draw any definite conclusion about the benefit of gangliosides in acute stroke. In fact, the poor design of randomisation procedures, the lack of intention-to-treat analysis in some studies, and the heterogeneous and incomplete presentation of the results made it difficult to perform a review. The number of excluded cases was too large to permit valid intention-to-treat analysis, and the incompleteness of follow-up information in some patients made interpretation of the sensitivity analysis difficult.</P>
<P>The case fatality rate was the only outcome measure that we could extract from all trials and it did not differ in the GM1 and the control group. There is a trend for decreasing case fatality with gangliosides treatment in favour of studies with small sample size, evident when data are sorted by study weight. This trend may be due to a publication bias of small trials which might have been published only when in favour of treatment and not submitted to publication when inconclusive or negative. For these reasons we considered it important to look for unpublished trials.</P>
<P>The overall mean difference in the Barthel index score obtained by pooling three trials (<LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>; <LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>; <LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>) did not show any benefit from GM1. This finding is in accordance with the two largest multicentre trials included in the meta-analysis (<LINK REF="STD-SASS-1994" TYPE="STUDY">SASS 1994</LINK>; <LINK REF="STD-Argentino-1989" TYPE="STUDY">Argentino 1989</LINK>). It was impossible to combine the disability results of these two studies as in the former only the mean Barthel score differences and in the latter only the mean Rankin scores without the standard deviations were available. The fact that the unpublished data on disability by one study (<LINK REF="STD-Heiss-1989" TYPE="STUDY">Heiss 1989</LINK>) differs significantly from the other published positive trials considered for this analysis (<LINK REF="STD-Hoffbrand-1988" TYPE="STUDY">Hoffbrand 1988</LINK>; <LINK REF="STD-Angeleri-1992" TYPE="STUDY">Angeleri 1992</LINK>), as shown by the test of heterogeneity, supports further the hypothesis of the publication bias of positive trials.</P>
<P>We were not able to confirm a beneficial effect of early with respect to delayed treatment, as suggested by the EST (<LINK REF="STD-EST-1994" TYPE="STUDY">EST 1994</LINK>) trial investigators. GM1 treatment delayed for over 48 hours was on the contrary associated with the lowest OR or case fatality.</P>
<P>Not only is the efficacy of gangliosides uncertain but also a severe form of acute motor neuropathy presenting clinically as Guillain-Barré syndrome has been described in a number of patients within two weeks of starting parenteral treatment with these drugs. Such cases were originally reported in Germany (<LINK REF="REF-Schonhofer-1991" TYPE="REFERENCE">Schonhofer 1991</LINK>) and later in the United States (<LINK REF="REF-Latov-1991" TYPE="REFERENCE">Latov 1991</LINK>), Italy (<LINK REF="REF-Nobile_x002d_Orazio-1994" TYPE="REFERENCE">Nobile-Orazio 1994</LINK>; <LINK REF="REF-Landi-1993" TYPE="REFERENCE">Landi 1993</LINK>), and Spain (<LINK REF="REF-Figueras-1992" TYPE="REFERENCE">Figueras 1992</LINK>). In addition, a clinical-immunologic study showed that exogenous gangliosides injections can be immunogenic, triggering IgG antigangliosides antibodies with specificity for motor nerve terminals and inducing an acute axonal Guillain-Barré syndrome within 15 days of gangliosides administration (<LINK REF="REF-Illa-1995" TYPE="REFERENCE">Illa 1995</LINK>). The estimated number of cases necessary to reveal a statistically significant increase in Guillain -Barré syndrome, from an expected rate of 0.001% (<LINK REF="REF-Govoni-1996" TYPE="REFERENCE">Govoni 1996</LINK>; <LINK REF="REF-Beghi-1996" TYPE="REFERENCE">Beghi 1996</LINK>) in the control group to 0.003% in the gangliosides group within 15 days of starting treatment (OR 3), is more than one million (1-ß = 0.95). This may explain why the epidemiological studies did not find any association between gangliosides and Guillain-Barré syndrome.</P>
<P>Only one of the population of 1136 cases treated with GM1 considered in this review developed Guillain-Barré syndrome. No cases of this syndrome were observed among controls.</P>
<P>In conclusion, although the number of patients may be too small to show a significant effect on case fatality and disability data are incomplete, this review did not reveal any data in favour of the use of GM1 treatment.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>As ganglioside therapy may have an unfavourable risk to benefit ratio (possible cause of Guillain-Barré syndrome versus absence of proof of therapeutic efficacy) we think that use of these drugs in clinical practice should be avoided.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Given the unpromising risk to benefit ratio of gangliosides for acute stroke, it is unlikely that these drugs will be tested further in clinical trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>None known<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-21 13:29:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>Dr Alfonso Ciccone, with Professor Livia Candelise, contributed in conceiving and designing this review. Dr Ciccone screened the results of the trials searches, and jointly with Professor Candelise, selected and assessed the quality of papers to be included in the review. Dr Ciccone extracted data from papers and compared them with those extracted independently by Professor Candelise. Dr Ciccone entered the data into RevMan, wrote the review, and discussed and modified the manuscript with Professor Candelise. Professor Livia Candelise searched for unpublished trials through enquiries to the epidemiological group of the gangliosides manufacturer, Fidia. Professor Candelise and Dr Ciccone contacted the main investigators of identified trials to request missing data.</P>
<P>Professor Candelise is the guarantor for this review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-21 13:45:26 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2008-08-21 13:43:44 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2008-08-21 13:43:44 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Angeleri-1992" NAME="Angeleri 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Angeleri F, Scarpino O, Martinazzo C, Mauro A, Magi A, Pelliccioni G, Rapex G, Bruno R</AU>
<TI>GM1 ganglioside therapy in acute ischemic stroke</TI>
<SO>Cerebrovasc Dis</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>163-169</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argentino-1989" MODIFIED="2008-08-21 13:41:08 +0100" MODIFIED_BY="Hazel Fraser" NAME="Argentino 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-08-21 13:41:08 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Argentino C, Sacchetti ML, Toni D, Savoini G, D'Arcangelo E, Erminio F, et al</AU>
<TI>GM1 ganglioside therapy in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>1143-1149</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Argentino C, Toni D, Sacchetti ML, Savoini G, Fieschi C for the Italian Acute Stroke Study Group</AU>
<TI>Ischemic stroke therapy with ganglioside GM1 within 12 hours from onset of symptoms (abstract)</TI>
<SO>Stroke</SO>
<YR>1990</YR>
<VL>21</VL>
<NO>8: suppl 1</NO>
<PG>1-96 (Abst OS-12-07)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oppenheimer S, Argentino C, Sacchetti ML, Toni D</AU>
<TI>GM1 ganglioside thrapy in acute ischemic stroke. [Letter]</TI>
<SO>Stroke</SO>
<YR>1990</YR>
<VL>21</VL>
<PG>825</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvestrini M, Argentino C, Giubilei F, Sacchetti ML, Savoini G, Fieschi C</AU>
<TI>Italian acute stroke hemodilution + drug (Protocol presentation)</TI>
<SO>Minerva Med</SO>
<YR>1988</YR>
<VL>79</VL>
<PG>695-696</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Argentino-plus-haemo" MODIFIED="2008-08-21 13:41:27 +0100" MODIFIED_BY="Hazel Fraser" NAME="Argentino plus haemo" YEAR="1989">
<REFERENCE MODIFIED="2008-08-21 13:41:27 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Argentino C, Sacchetti ML, Toni D, Savoini G, D'Arcangelo E, Erminio F, et al</AU>
<TI>GM1 ganglioside therapy in acute ischemic stroke</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>1143-1149.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bassi-1984" MODIFIED="2008-08-21 13:43:44 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bassi 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apollonio I, Frattola L, Massarotti M</AU>
<TI>Trial of ganglioside GM1 in acute stroke [Letter]</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1989</YR>
<VL>52</VL>
<PG>685-686</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bassi S, Albizzati MG, Sbacchi M, Frattola L, Massarotti M</AU>
<TI>Double-blind evaluation of monosialoganglioside (GM1) therapy in stroke</TI>
<SO>J Neurosci Res</SO>
<YR>1984</YR>
<VL>12</VL>
<PG>493-498</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-21 13:43:44 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bassi S, Albizzati MG, Sbacchi M, Frattola L, Massarotti M</AU>
<TI>Monosialoganglioside therapy in stroke [Letter]</TI>
<SO>Stroke</SO>
<YR>1985</YR>
<VL>16</VL>
<PG>899-900</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Battistin-1985" NAME="Battistin 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Battistin L, Cesari A, Galligioni F, Marin G, Massarotti M, Paccagnella D, Pellegrini A, Testa G, Tonin P</AU>
<TI>Effects of GM1 gangliosides in cerebrovascular diseases: a double blind trial in 40 cases</TI>
<SO>Eur Neurol</SO>
<YR>1985</YR>
<VL>24</VL>
<PG>343-351</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EST-1994" NAME="EST 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carolei A</AU>
<TI>The Early Stroke Trial (EST): safety and efficacy of GM1 in acute ischaemic stroke [Abstract]</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>suppl</NO>
<PG>A263</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fieschi C, Carolei A, Argentino C, Bottacchi E, Brambilla GL, Gambi D, Inzitari D, Mamoli A, Senin U, Gerstenbrand F, Ott EO, Bes A, Bogousslavsky J, Portera-Sanchez A, Horowitz S, Einhaeupl K, Hopf HC, Lenzi GL, Bruno R</AU>
<TI>Early Stroke Trial (EST): a multicenter study on acute ischemic stroke [Abstract]</TI>
<SO>International Conference on Stroke</SO>
<YR>1991</YR>
<PG>67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fiorentini R, Friday G, Dorsey F</AU>
<TI>Clinical studies of monosialotetrahexosyl-ganglioside for the treatment of central nervous system injuries</TI>
<SO>J Neurochem</SO>
<YR>1993</YR>
<VL>61 (Suppl)</VL>
<PG>S7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lenzi GL, Grigoletto F, Gent M, Roberts RS, Walker MD, Easton D, Carolei A, Dorsey FC, Rocca WA, Bruno R, Patarnello F, Fieschi C, Early Stroke Trial Group</AU>
<TI>Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the Early Stroke Trial</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>1552-1558</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rocca WA, Dorsey FC, Grigoletto F, Gent M, Roberts RS, Walker MD, Easton JD, Bruno R, Carolei A, Sancesario G, Fieschi C</AU>
<TI>Design and baseline results of the monosialoganglioside Early Stroke Trial</TI>
<SO>Stroke</SO>
<YR>1992</YR>
<VL>23</VL>
<PG>519-526</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giraldi-1990" NAME="Giraldi 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giraldi C, Masi MC, Manetti M, Carabelli E, Martini A</AU>
<TI>A pilot study with monosialoganglioside GM1 on acute cerebral ischemia</TI>
<SO>Acta Neurol (Napoli)</SO>
<YR>1990</YR>
<VL>12</VL>
<PG>214-221</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Heiss-1989" NAME="Heiss 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Heiss WD, Pawlik G, Helbold I, Beil C, Herholz K, Szelies B, v Einsiedel R, Wienhard K</AU>
<TI>Can PET estimate functional recovery and indicate therapeutic strategy in stroke?</TI>
<SO>Pharmacology of cerebral ischemia</SO>
<YR>1989</YR>
<PG>433-438</PG>
<EN>1</EN>
<ED>Krieglstein J</ED>
<PB>Wissenschaftliche Verlagsgesellschaft mbH</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoffbrand-1988" NAME="Hoffbrand 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffbrand BI, Bingley PJ, Oppenheimer SM, Sheldon CD</AU>
<TI>Trial of ganglioside GM1 in acute stroke</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1988</YR>
<VL>51</VL>
<PG>1213-1214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirczynska-1994" NAME="Kirczynska 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirczynska-Zaderwialy A, Kruszewska J, Lechowicz W, Czlonkowska A</AU>
<TO>Zastosowanie gangliozydu GM1 we wczesney fazie udaru mózgu</TO>
<SO>Neur Neurochir Pol</SO>
<YR>1993</YR>
<VL>28</VL>
<PG>643-649</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monaco-1991" NAME="Monaco 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Monaco P, Pastore L, Cottone S, Conti A, Bellinvia S</AU>
<TI>Early treatment of patients with ischemic stroke: a double blind study with monosialotetraesosiganglioside (GM1) [Abstract]</TI>
<SO>Proceedings of the 1st International Conference on Stroke, Geneva, Switzerland</SO>
<YR>1991</YR>
<PG>7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SASS-1994" NAME="SASS 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alter M, SASS Study Group</AU>
<TI>The Sygen (GM1) Acute Stroke Study (SASS) [Abstract]</TI>
<SO>J Stroke Crerebrovasc Dis</SO>
<YR>1992</YR>
<VL>1</VL>
<NO>Suppl 1</NO>
<PG>s12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Fiorentini R, Friday G, Dorsey F</AU>
<TI>Clinical studies of monosialotetrahexosyl-ganglioside for the treatment of central nervous system injuries</TI>
<SO>J Neurochem</SO>
<YR>1993</YR>
<VL>61 (Suppl)</VL>
<PG>S7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>SASS investigators</AU>
<TI>Ganglioside GM1 in acute ischemic stroke. The SASS trial</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<PG>1141-1148</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wender-1993" NAME="Wender 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wender M, Mularek J, Godlewski A, Losy J, Michatowska-Wender G, Sniata-Kamasa M, Wojcicka M</AU>
<TO>Proby leczenia monosialogangliozydem (Sygenem) chorych z niedokrwiennym udarem mozgu</TO>
<SO>Neur Neurochir Pol</SO>
<YR>1993</YR>
<VL>27</VL>
<PG>31-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Jamieson-1989" NAME="Jamieson 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jamieson DG, Reivich M, Alves W, Fazekas F, Kushner M, Chawluk J, Blackman D, Silver F, Alavi A</AU>
<TI>The effect of ganglioside (GM1) treatment in acute ischemic infarction: a positron emission tomography study [Abstract]</TI>
<SO>J Cereb Blood Flow Metab</SO>
<YR>1989</YR>
<VL>9</VL>
<NO>1</NO>
<PG>s602-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Massarotti-1989" NAME="Massarotti 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Massarotti M</AU>
<TI>Neuroplasticity and Gangliosides: a clinical approach</TI>
<SO>J Neuro Rehab</SO>
<YR>1989</YR>
<VL>3</VL>
<PG>55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Papo-1991" NAME="Papo 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Papo I, Benedetti A, Carteri A, Merli GA, Mingrino S, Bruno R</AU>
<TI>Monosialoganglioside in subarachnoid hemorrhage</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<PG>22-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toso-1992" NAME="Toso 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>D'Agnolo B, Feruglio FS, Basaglia N, Toso V, Saracino A, Scarpa R, Donati G, Falezza G, Bruno R, Salvato G</AU>
<TI>GM1 in acute stroke. A multicenter study</TI>
<SO>J Neurochem</SO>
<YR>1991</YR>
<VL>57 (Suppl)</VL>
<PG>S102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Toso V, D'Agnolo B, Feruglio FS, Basaglia N, Donati G, Falezza G, Saracino A, Scarpa R, Salvato G, Bruno R</AU>
<TI>GM1 therapy of acute stroke. A multicenter trial [Abstract]</TI>
<SO>Cerebrovasc Dis</SO>
<YR>1992</YR>
<VL>2</VL>
<PG>210</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-21 13:45:26 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-21 13:45:26 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Beghi-1996" NAME="Beghi 1996" TYPE="JOURNAL_ARTICLE">
<AU>Beghi E, Kurland LT, Mulder DW, Wiederholt WC</AU>
<TI>Guillain-Barré syndrome: clinico-epidemiological features and effect of influenza vaccine</TI>
<SO>Arch Neurol</SO>
<YR>1996</YR>
<VL>42</VL>
<PG>1053-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Favaron-1988" NAME="Favaron 1988" TYPE="JOURNAL_ARTICLE">
<AU>Favaron M, Manev H, Alho H, Bertolino M, Ferret B, Guidotti A, Costa E</AU>
<TI>Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex</TI>
<SO>Proc Natl Acad Sci USA</SO>
<YR>1988</YR>
<VL>85</VL>
<PG>7351-7355</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Figueras-1992" NAME="Figueras 1992" TYPE="JOURNAL_ARTICLE">
<AU>Figueras A, Morales-Olivas FJ, Capella D, et al</AU>
<TI>Bovine gangliosides and acute motor polyneuropathy</TI>
<SO>Br Med J</SO>
<YR>1992</YR>
<VL>305</VL>
<PG>1330-1331</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Govoni-1996" NAME="Govoni 1996" TYPE="JOURNAL_ARTICLE">
<AU>Govoni V, Granieri E, Casetta I, et al</AU>
<TI>The incidence of Guillain-Barré syndrome in Ferrara, Italy: is the disease really increasing?</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1996</YR>
<VL>137</VL>
<PG>62-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Illa-1995" NAME="Illa 1995" TYPE="JOURNAL_ARTICLE">
<AU>Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas C</AU>
<TI>Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides</TI>
<SO>Ann Neurol</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>218-224</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landi-1993" MODIFIED="2008-08-21 13:45:18 +0100" MODIFIED_BY="Hazel Fraser" NAME="Landi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Landi G, D'Alessandro R, Curró-Dossi B, Ricci S, Simone IL, Ciccone A</AU>
<TI>Guillain-Barré syndrome after exogenous gangliosides in Italy</TI>
<SO>Br Med J</SO>
<YR>1993</YR>
<VL>307</VL>
<PG>1463-1464</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Latov-1991" MODIFIED="2008-08-21 13:45:23 +0100" MODIFIED_BY="Hazel Fraser" NAME="Latov 1991" TYPE="JOURNAL_ARTICLE">
<AU>Latov N, Koski CL, Walicke PA</AU>
<TI>Guillain-Barré syndrome and parenteral gangliosides</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>757</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leeden-1984" MODIFIED="2008-08-21 13:45:26 +0100" MODIFIED_BY="Hazel Fraser" NAME="Leeden 1984" TYPE="JOURNAL_ARTICLE">
<AU>Leeden RW</AU>
<TI>Biology of gangliosides: neuritogenic and neuronotrophic properties</TI>
<SO>J Neurosci Res</SO>
<YR>1984</YR>
<VL>12</VL>
<PG>147-159</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nobile_x002d_Orazio-1994" NAME="Nobile-Orazio 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nobile-Orazio E, Carpo M, Scarlato G</AU>
<TI>Gangliosides. Their role in clinical neurology</TI>
<SO>Drugs</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>4</NO>
<PG>576-585</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schonhofer-1991" NAME="Schonhofer 1991" TYPE="JOURNAL_ARTICLE">
<AU>Schonhofer PS</AU>
<TI>Guillain-Barré&#8218; syndrome and parenteral gangliosides</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>338</VL>
<PG>757</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skaper-1985" NAME="Skaper 1985" TYPE="JOURNAL_ARTICLE">
<AU>Skaper SD, Katoh-Semba R, Varon S</AU>
<TI>GM1 ganglioside accelerates neurite outgrowth from primary peripheral and central neurons under selected culture conditions</TI>
<SO>Dev Brain Res</SO>
<YR>1985</YR>
<VL>23</VL>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-21 13:49:42 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-21 13:49:42 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-21 13:33:53 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Angeleri-1992">
<CHAR_METHODS MODIFIED="2008-08-21 13:29:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>Multicentre trial, double blind, no intention-to-treat analysis<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:29:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>112 patients within 48 hours after first ischaemic stroke (clinical or CT-scan based)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 300 mg iv first day (200 mg + 100 mg), 100 mg iv daily from day 2 to day 21 versus saline solution (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:29:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Mathew's rating scale, modified by Frithz and Werner 1975, mean and SD), disability (Barthel index, mean and SD), and case fatality at 180 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:33:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>13 early withdrawals (7 GM1 and 6 placebo) for ineligibility (7 haemorrhagic stroke, 4 concomitant severe disease and 2 tumour)<BR/>2 withdrawals or drop outs (2 GM1) before completion of follow up (1 dermatitis and 1 lost to follow up)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:34:23 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Argentino-1989">
<CHAR_METHODS MODIFIED="2008-08-21 13:29:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>Multicentre trial, double blind, 2 X 2 factorial with haemodilution treatment, intention-to-treat analysis of case fatality and neurological deficit<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:30:00 +0100" MODIFIED_BY="Hazel Fraser">
<P>502 patients within 12 hours of first hemispheric stroke diagnosed clinically (CT-scan in all cases after randomisation, 40 haemorrhagic stroke)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:30:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Four treatment groups: GM1 (100 mg iv daily for 15 days), GM1 plus haemodilution, placebo (saline solution), placebo plus haemodilution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:30:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Canadian Neurological Scale, mean without SD), disability (modified Rankin, mean without SD) and mortality at 120 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:34:23 +0100" MODIFIED_BY="Hazel Fraser">
<P>75 early withdrawals (47 GM1 and 28 placebo) for ineligibility (23 previous stroke, 40 haemorrhagic stroke, 3 vertebrobasilar stroke, 9 tumour)<BR/>32 withdrawals or drop outs (16 GM1 and 16 pl) before completion of follow up because "they did not want to continue in the study"<BR/>Data on survival apparently available in all cases</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:49:42 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Argentino-plus-haemo">
<CHAR_METHODS MODIFIED="2008-08-21 13:49:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>Multicentre trial, double blind, 2 X 2 factorial with haemodilution treatment, intention-to-treat analysis of case fatality and neurological deficit<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:49:19 +0100" MODIFIED_BY="Hazel Fraser">
<P>502 patients within 12 hours of first hemispheric stroke diagnosed clinically (CT-scan in all cases after randomisation, 40 haemorrhagic stroke)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:49:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>Four treatment groups: GM1 (100 mg iv daily for 15 days), GM1 plus haemodilution, placebo (saline solution), placebo plus haemodilution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:49:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Canadian Neurological Scale, mean without SD), disability (modified Rankin, mean without SD) and mortality at 120 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:49:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>75 early withdrawals (47 GM1 and 28 placebo) for ineligibility (23 previous stroke, 40 haemorrhagic stroke, 3 vertebrobasilar stroke, 9 tumour)<BR/>32 withdrawals or drop outs (16 GM1 and 16 pl) before completion of follow up because "they did not want to continue in the study"<BR/>Data on survival apparently available in all cases</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:35:21 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Bassi-1984">
<CHAR_METHODS MODIFIED="2008-08-21 13:30:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, double blind, no intention-to-treat analysis<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:30:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>38 patients within 15 days of ischaemic or haemorrhagic first stroke <BR/>CT-scan in all cases (number of haemorrhages unknown)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 20 mg im twice a day for 6 weeks versus saline solution (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:30:31 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Mathew's rating scale, modified by Frithz and Werner 1975, mean and SD) at 42 days<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:35:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>No early withdrawals<BR/>5 withdrawals during follow up: 4 GM1 (1 not treated and 3 neurological deterioration) and 1 placebo (stroke recurrence)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:35:58 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Battistin-1985">
<CHAR_METHODS MODIFIED="2008-08-21 13:30:36 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, double blind, no intention-to-treat analysis<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:30:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>40 patients about 10 days after ischaemic or haemorrhagic stroke<BR/>CT-scan in all cases (5 haemorrhages)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 40 mg im daily for 6 weeks versus saline solution (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:35:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improvement in the clinical examination (3 = severe, 2 = moderate, 1 = mild, 0 = none, score for each patient), EEG, flash evoked potentials, and CT-scan, at 42 days <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:35:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>No withdrawals<BR/>3 drop outs (1 GM1 and 2 placebo) for "lack of compliance"<BR/>Time of start of treatment not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:36:34 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-EST-1994">
<CHAR_METHODS MODIFIED="2008-08-21 13:30:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>Multicentre trial, double blind, intention-to-treat analysis of case fatality and neurologic deficit<BR/>Randomisation stratified by severity and by centre</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:30:56 +0100" MODIFIED_BY="Hazel Fraser">
<P>805 patients within 5 hours of ischaemic hemispheric stroke<BR/>Excluded comatose patients<BR/>CT-scan in all cases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>First day: GM1 200 mg iv within 5 hours of onset, GM1 100 mg iv 12 hours later; from day 2 to day 10: GM1 100 mg iv once a day; from day 11 to day 21 GM1 100 mg im daily; versus saline solution (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:30:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological deficit (Canadian Neurological scale, mean score difference without SD) and case fatality at 120 days<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:36:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>13 withdrawals (5 GM1 and 8 placebo) for incorrect diagnosis with complete data on survival at the end of follow up<BR/>5 drop outs (5 placebo) after 2, 7, 14, and 61 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:36:53 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Giraldi-1990">
<CHAR_METHODS MODIFIED="2008-08-21 13:31:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, open, no intention-to-treat analysis<BR/>Possibly incorrect randomisation procedure (sequential randomisation according to severity on admission)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:31:05 +0100" MODIFIED_BY="Hazel Fraser">
<P>60 patients after first carotid ischaemic stroke between 24 and 48 hours of the onset of neurological symptoms<BR/>CT-scan in all cases<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 100 mg iv daily for 21 days and then 40 mg im daily + usual therapy for up to 2 months versus usual therapy alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:31:07 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Mathew's rating scale, modified by Frithz and Werner 1975, mean and SD on graph), disability (Barthel index, mean and SD only on graph), case fatality at 120 days<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:36:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>No mention of withdrawals and drop outs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:37:06 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Heiss-1989">
<CHAR_METHODS MODIFIED="2008-08-21 13:31:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, double blind, no intention-to-treat analysis<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:31:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>25 patients after ischaemic hemispheric stroke within 48 hours of onset<BR/>CT-scan in all cases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:41 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 100 mg iv daily over 3 weeks plus haemodilution versus "drug free solvent" plus haemodilution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:31:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>Regional metabolic rate for glucose by positron emission tomography, improved neurological score (Stroke-Index) and degree of disability (Barthel index, mean and SD) at 90 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:37:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>No withdrawals<BR/>5 drop outs (2 GM1 and 3 placebo)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:37:38 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Hoffbrand-1988">
<CHAR_METHODS MODIFIED="2008-08-21 13:31:22 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, double blind, no intention-to-treat analysis<BR/>Randomisation stratified by severity</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:37:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>54 patients after ischaemic or haemorrhagic hemispheric stroke with limb weakness within 72 hours of the onset of neurological symptoms<BR/>CT-scan within 5 to 6 days (10 haemorrhages)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 100 mg im daily for 28 days versus saline solution (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:31:25 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (results not shown) and degree of disability (Barthel index, mean and SD) at 180 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:37:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>One early withdrawal (unknown treatment group) for tumour<BR/>4 withdrawals or drop outs before completition of follow up: 2 GM1 (1 epilepsy, 1 haematoma) and 2 placebo (1 stroke recurrence and 1 lost to follow up)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:32:51 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Kirczynska-1994">
<CHAR_METHODS MODIFIED="2008-08-21 13:31:27 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, open, no intention-to-treat analysis<BR/>Method of randomisation not described<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 patients after ischaemic stroke within 48 hours of onset<BR/>CT-scan in all cases<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:51 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 100 mg iv daily for 5 days and then 100 mg im daily + usual therapy versus usual therapy alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:31:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Canadian neurologic scale, mean and SD) and degree of disability (Rankin index, mean and SD) at 30 days<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>2 withdrawals (unknown treatment group)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:38:02 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Monaco-1991">
<CHAR_METHODS MODIFIED="2008-08-21 13:31:30 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, double blind, no intention-to-treat analysis<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:31:38 +0100" MODIFIED_BY="Hazel Fraser">
<P>180 patients within 10 hours of ischaemic stroke<BR/>CT-scan in all cases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:32:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 100 mg iv for 15 days versus placebo (not specified)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:31:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Canadian Neurological Scale, mean and SD not shown) at 15 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:38:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>No withdrawals<BR/>1 drop out in placebo group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:38:29 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-SASS-1994">
<CHAR_METHODS MODIFIED="2008-08-21 13:31:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>Multicentre trial, double blind, intention-to-treat analysis for case fatality<BR/>Method of randomisation not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:31:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>287 patients after ischaemic anterior circulation stroke within 48 hours of onset of neurological symptoms<BR/>CT-scan in all cases</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:33:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 100 mg im daily for 28 days versus saline solution (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:31:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological score (Toronto Stroke scale, mean and SD), disability (Barthel index, mean difference without SD), case fatality at 84 days<BR/>Secondary outcomes were improvements on Fugl-Meyer Scale and on a neuropsychological battery<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:38:29 +0100" MODIFIED_BY="Hazel Fraser">
<P>12 withdrawals (unknown treatment group): 4 incorrect diagnosis, 2 not treated, 6 not evaluated after baseline<BR/>52 drop outs (28 GM1 and 24 placebo) of whom 11 (4 GM1 and 7 placebo) "refused/lost to follow up/unreliable"</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-21 13:38:37 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-Wender-1993">
<CHAR_METHODS MODIFIED="2008-08-21 13:31:52 +0100" MODIFIED_BY="Hazel Fraser">
<P>One centre trial, double blind, no intention-to-treat analysis<BR/>Randomisation procedure not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-21 13:31:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>85 patients within 3 days of onset of stroke<BR/>No CT-scan</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-21 13:33:08 +0100" MODIFIED_BY="Hazel Fraser">
<P>GM1 40 mg im daily for 6 weeks versus vitamin PP im (placebo)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-21 13:31:56 +0100" MODIFIED_BY="Hazel Fraser">
<P>Improved neurological deficit (Mathew's rating scale, mean and SD) at 42 days<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-21 13:38:37 +0100" MODIFIED_BY="Hazel Fraser">
<P>No withdrawals or drop outs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Jamieson-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Impossible to account for deaths and/or number of disable patients in the different allocation groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Massarotti-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Impossible to account for deaths and/or disable patients in the different allocation groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Papo-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>The aim of this study was to evaluate efficacy of GM1 in patients with subarachnoid haemorrhage and not with stroke.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toso-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Impossible to account for deaths and/or disable patients in the different allocation groups.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Angeleri-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Argentino-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Argentino-plus-haemo">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bassi-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Battistin-1985">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-EST-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Giraldi-1990">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heiss-1989">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hoffbrand-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Kirczynska-1994">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Monaco-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SASS-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Wender-1993">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Ganglioside versus control. Intention-to-treat analysis</NAME>
<DICH_OUTCOME CHI2="11.37827016755726" CI_END="1.1311711625992966" CI_START="0.7274804520680037" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9071410633049447" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="200" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.053528324950317764" LOG_CI_START="-0.13817867199574296" LOG_EFFECT_SIZE="-0.04232517352271258" METHOD="PETO" NO="1" P_CHI2="0.4968090535417786" P_Q="1.0" P_Z="0.3867952597640302" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1140" TOTAL_2="1125" WEIGHT="99.99999999999999" Z="0.8654437977270664">
<NAME>Case fatality at the end of scheduled follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.1294051885293448" CI_START="0.10402872235387907" EFFECT_SIZE="0.34276898748654266" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05284977857040849" LOG_CI_START="-0.9828467353396151" LOG_EFFECT_SIZE="-0.4649984783846033" ORDER="12504" O_E="-2.8928571428571432" SE="0.6083732590511755" STUDY_ID="STD-Angeleri-1992" TOTAL_1="55" TOTAL_2="57" VAR="2.7018408714837285" WEIGHT="3.426185709469401"/>
<DICH_DATA CI_END="1.7271775454183662" CI_START="0.5309597745983308" EFFECT_SIZE="0.9576334372851827" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.23733698321438204" LOG_CI_START="-0.27493837973154384" LOG_EFFECT_SIZE="-0.018800698258580887" ORDER="12505" O_E="-0.47808764940239" SE="0.3009130839983804" STUDY_ID="STD-Argentino-1989" TOTAL_1="121" TOTAL_2="130" VAR="11.043782797098457" WEIGHT="14.004544530086925"/>
<DICH_DATA CI_END="1.4648532443900233" CI_START="0.3995663746157907" EFFECT_SIZE="0.7650530048337176" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.16579411728799023" LOG_CI_START="-0.3984110668255989" LOG_EFFECT_SIZE="-0.11630847476880435" ORDER="12516" O_E="-2.4382470119521926" SE="0.33141691800902634" STUDY_ID="STD-Argentino-plus-haemo" TOTAL_1="128" TOTAL_2="123" VAR="9.10438577165442" WEIGHT="11.545208584844953"/>
<DICH_DATA CI_END="1.2369510716543397" CI_START="0.011781544855070231" EFFECT_SIZE="0.12071948696968021" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.09235252118870996" LOG_CI_START="-1.9287977589510314" LOG_EFFECT_SIZE="-0.9182226188811609" ORDER="12506" O_E="-1.5" SE="1.1872336794093272" STUDY_ID="STD-Bassi-1984" TOTAL_1="19" TOTAL_2="19" VAR="0.7094594594594595" WEIGHT="0.8996606303142619"/>
<DICH_DATA CI_END="5.057289137848246" CI_START="0.04849784079915892" EFFECT_SIZE="0.49524499339486505" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7039177840423391" LOG_CI_START="-1.3142775964469091" LOG_EFFECT_SIZE="-0.305179906202285" ORDER="12507" O_E="-0.5" SE="1.1854979567276382" STUDY_ID="STD-Battistin-1985" TOTAL_1="20" TOTAL_2="20" VAR="0.7115384615384616" WEIGHT="0.902296998461703"/>
<DICH_DATA CI_END="1.5084656091498456" CI_START="0.7587381443691852" EFFECT_SIZE="1.0698272744378348" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="79" LOG_CI_END="0.178535413333211" LOG_CI_START="-0.11990808191374511" LOG_EFFECT_SIZE="0.029313665709732904" ORDER="12508" O_E="2.196273291925465" SE="0.1753071864271894" STUDY_ID="STD-EST-1994" TOTAL_1="404" TOTAL_2="401" VAR="32.538727188869515" WEIGHT="41.2621347450438"/>
<DICH_DATA CI_END="2.4816753242139535" CI_START="0.1295680244175102" EFFECT_SIZE="0.5670500586404044" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3947449624464862" LOG_CI_START="-0.8875021630674835" LOG_EFFECT_SIZE="-0.24637860031049863" ORDER="12509" O_E="-1.0" SE="0.7531983087525438" STUDY_ID="STD-Giraldi-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.7627118644067796" WEIGHT="2.2352827153829087"/>
<DICH_DATA CI_END="6.294865784357986" CI_START="0.002462936324636916" EFFECT_SIZE="0.12451447144412302" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.798986474756175" LOG_CI_START="-2.608546816019724" LOG_EFFECT_SIZE="-0.9047801706317745" ORDER="12515" O_E="-0.52" SE="2.001601922563589" STUDY_ID="STD-Heiss-1989" TOTAL_1="13" TOTAL_2="12" VAR="0.24960000000000004" WEIGHT="0.3165160324982199"/>
<DICH_DATA CI_END="1.487985127506384" CI_START="0.13233219357866122" EFFECT_SIZE="0.443743547485869" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.17259859043419543" LOG_CI_START="-0.8783344884449336" LOG_EFFECT_SIZE="-0.3528679490053691" ORDER="12510" O_E="-2.132075471698113" SE="0.6173232927362409" STUDY_ID="STD-Hoffbrand-1988" TOTAL_1="27" TOTAL_2="26" VAR="2.6240655037379845" WEIGHT="3.3275593039206313"/>
<DICH_DATA CI_END="2.220082799208475" CI_START="0.2900688168348892" EFFECT_SIZE="0.8024816451744498" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.34636917200414247" LOG_CI_START="-0.5374989564936012" LOG_EFFECT_SIZE="-0.09556489224472933" ORDER="12511" O_E="-0.816326530612244" SE="0.5191885138973733" STUDY_ID="STD-Kirczynska-1994" TOTAL_1="48" TOTAL_2="50" VAR="3.7097944584945273" WEIGHT="4.704364677029526"/>
<DICH_DATA CI_END="3.583833649660221" CI_START="0.6048628005221561" EFFECT_SIZE="1.4723205010930944" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5543478428675159" LOG_CI_START="-0.2183431240804078" LOG_EFFECT_SIZE="0.168002359393554" ORDER="12512" O_E="1.8777777777777782" SE="0.4538824988671837" STUDY_ID="STD-Monaco-1991" TOTAL_1="91" TOTAL_2="89" VAR="4.8541492516725295" WEIGHT="6.155513070086506"/>
<DICH_DATA CI_END="2.796057667297241" CI_START="0.5430845037511757" EFFECT_SIZE="1.2322725310189266" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.44654612427346857" LOG_CI_START="-0.26513258908984144" LOG_EFFECT_SIZE="0.09070676759181351" ORDER="12513" O_E="1.1951219512195124" SE="0.4180435990960555" STUDY_ID="STD-SASS-1994" TOTAL_1="147" TOTAL_2="140" VAR="5.722118452636002" WEIGHT="7.25617880654327"/>
<DICH_DATA CI_END="2.4399009085816066" CI_START="0.26580415325384926" EFFECT_SIZE="0.805317201498162" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3873721887444322" LOG_CI_START="-0.5754382373844955" LOG_EFFECT_SIZE="-0.09403302432003176" ORDER="12514" O_E="-0.6769230769230763" SE="0.5655596102966064" STUDY_ID="STD-Wender-1993" TOTAL_1="37" TOTAL_2="28" VAR="3.1263905325443786" WEIGHT="3.964554196317882"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.378270167557261" CI_END="1.1311711625992966" CI_START="0.7274804520680037" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9071410633049447" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="200" I2="0.0" I2_Q="21.4162989961093" ID="CMP-001.02" LOG_CI_END="0.053528324950317764" LOG_CI_START="-0.13817867199574296" LOG_EFFECT_SIZE="-0.04232517352271258" METHOD="PETO" NO="2" P_CHI2="0.4968090535417785" P_Q="0.28184757968936014" P_Z="0.38679525976403006" Q="3.8175855319558814" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1140" TOTAL_2="1125" WEIGHT="100.0" Z="0.8654437977270666">
<NAME>Case fatality according to interval stroke-randomisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5084656091498456" CI_START="0.7587381443691852" DF="0" EFFECT_SIZE="1.0698272744378348" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="79" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.178535413333211" LOG_CI_START="-0.11990808191374511" LOG_EFFECT_SIZE="0.029313665709732904" NO="1" P_CHI2="1.0" P_Z="0.700220752805099" STUDIES="1" TAU2="0.0" TOTAL_1="404" TOTAL_2="401" WEIGHT="41.26213474504381" Z="0.38502249143263445">
<NAME>within 5 h</NAME>
<DICH_DATA CI_END="1.5084656091498456" CI_START="0.7587381443691852" EFFECT_SIZE="1.0698272744378348" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="79" LOG_CI_END="0.178535413333211" LOG_CI_START="-0.11990808191374511" LOG_EFFECT_SIZE="0.029313665709732904" ORDER="12517" O_E="2.196273291925465" SE="0.1753071864271894" STUDY_ID="STD-EST-1994" TOTAL_1="404" TOTAL_2="401" VAR="32.538727188869515" WEIGHT="41.26213474504381"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.3569428654565132" CI_END="1.419686684564233" CI_START="0.6482278325441768" DF="2" EFFECT_SIZE="0.959312473820132" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="63" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.15219250904591136" LOG_CI_START="-0.18827232587885892" LOG_EFFECT_SIZE="-0.018039908416473748" NO="2" P_CHI2="0.5073920283554114" P_Z="0.8354618523756655" STUDIES="3" TAU2="0.0" TOTAL_1="340" TOTAL_2="342" WEIGHT="31.705266185018388" Z="0.20770174863141">
<NAME>between 6-12 h</NAME>
<DICH_DATA CI_END="1.7271775454183662" CI_START="0.5309597745983308" EFFECT_SIZE="0.9576334372851827" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.23733698321438204" LOG_CI_START="-0.27493837973154384" LOG_EFFECT_SIZE="-0.018800698258580887" ORDER="12518" O_E="-0.47808764940239" SE="0.3009130839983804" STUDY_ID="STD-Argentino-1989" TOTAL_1="121" TOTAL_2="130" VAR="11.043782797098457" WEIGHT="14.004544530086926"/>
<DICH_DATA CI_END="1.4648532443900233" CI_START="0.3995663746157907" EFFECT_SIZE="0.7650530048337176" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.16579411728799023" LOG_CI_START="-0.3984110668255989" LOG_EFFECT_SIZE="-0.11630847476880435" ORDER="12520" O_E="-2.4382470119521926" SE="0.33141691800902634" STUDY_ID="STD-Argentino-plus-haemo" TOTAL_1="128" TOTAL_2="123" VAR="9.10438577165442" WEIGHT="11.545208584844955"/>
<DICH_DATA CI_END="3.583833649660221" CI_START="0.6048628005221561" EFFECT_SIZE="1.4723205010930944" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5543478428675159" LOG_CI_START="-0.2183431240804078" LOG_EFFECT_SIZE="0.168002359393554" ORDER="12519" O_E="1.8777777777777782" SE="0.4538824988671837" STUDY_ID="STD-Monaco-1991" TOTAL_1="91" TOTAL_2="89" VAR="4.8541492516725295" WEIGHT="6.155513070086507"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.02686045929108" CI_END="1.2660971097219749" CI_START="0.44651467560599856" DF="4" EFFECT_SIZE="0.7518849248609789" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="36" I2="0.6670322839001147" ID="CMP-001.02.03" LOG_CI_END="0.10246701737088532" LOG_CI_START="-0.3501642625761894" LOG_EFFECT_SIZE="-0.12384862260265206" NO="3" P_CHI2="0.40238311036774066" P_Z="0.2834651507545286" STUDIES="5" TAU2="0.0" TOTAL_1="293" TOTAL_2="289" WEIGHT="17.938527940923326" Z="1.0725676752365605">
<NAME>between 13-48 h</NAME>
<DICH_DATA CI_END="1.1294051885293448" CI_START="0.10402872235387907" EFFECT_SIZE="0.34276898748654266" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.05284977857040849" LOG_CI_START="-0.9828467353396151" LOG_EFFECT_SIZE="-0.4649984783846033" ORDER="12521" O_E="-2.8928571428571432" SE="0.6083732590511755" STUDY_ID="STD-Angeleri-1992" TOTAL_1="55" TOTAL_2="57" VAR="2.7018408714837285" WEIGHT="3.4261857094694013"/>
<DICH_DATA CI_END="2.4816753242139535" CI_START="0.1295680244175102" EFFECT_SIZE="0.5670500586404044" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3947449624464862" LOG_CI_START="-0.8875021630674835" LOG_EFFECT_SIZE="-0.24637860031049863" ORDER="12522" O_E="-1.0" SE="0.7531983087525438" STUDY_ID="STD-Giraldi-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.7627118644067796" WEIGHT="2.2352827153829087"/>
<DICH_DATA CI_END="6.294865784357986" CI_START="0.002462936324636916" EFFECT_SIZE="0.12451447144412302" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.798986474756175" LOG_CI_START="-2.608546816019724" LOG_EFFECT_SIZE="-0.9047801706317745" ORDER="12525" O_E="-0.52" SE="2.001601922563589" STUDY_ID="STD-Heiss-1989" TOTAL_1="13" TOTAL_2="12" VAR="0.24960000000000004" WEIGHT="0.31651603249821997"/>
<DICH_DATA CI_END="2.220082799208475" CI_START="0.2900688168348892" EFFECT_SIZE="0.8024816451744498" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.34636917200414247" LOG_CI_START="-0.5374989564936012" LOG_EFFECT_SIZE="-0.09556489224472933" ORDER="12523" O_E="-0.816326530612244" SE="0.5191885138973733" STUDY_ID="STD-Kirczynska-1994" TOTAL_1="48" TOTAL_2="50" VAR="3.7097944584945273" WEIGHT="4.704364677029527"/>
<DICH_DATA CI_END="2.796057667297241" CI_START="0.5430845037511757" EFFECT_SIZE="1.2322725310189266" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.44654612427346857" LOG_CI_START="-0.26513258908984144" LOG_EFFECT_SIZE="0.09070676759181351" ORDER="12524" O_E="1.1951219512195124" SE="0.4180435990960555" STUDY_ID="STD-SASS-1994" TOTAL_1="147" TOTAL_2="140" VAR="5.722118452636002" WEIGHT="7.256178806543271"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.176881310853787" CI_END="1.063231277551495" CI_START="0.24599037433532348" DF="3" EFFECT_SIZE="0.5114143720799372" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="22" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.026627743958209542" LOG_CI_START="-0.6090818866154912" LOG_EFFECT_SIZE="-0.29122707132864084" NO="4" P_CHI2="0.5365164516268645" P_Z="0.07253088881341081" STUDIES="4" TAU2="0.0" TOTAL_1="103" TOTAL_2="93" WEIGHT="9.09407112901448" Z="1.7957713511814999">
<NAME>over 48 h</NAME>
<DICH_DATA CI_END="1.2369510716543397" CI_START="0.011781544855070231" EFFECT_SIZE="0.12071948696968021" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.09235252118870996" LOG_CI_START="-1.9287977589510314" LOG_EFFECT_SIZE="-0.9182226188811609" ORDER="12526" O_E="-1.5" SE="1.1872336794093272" STUDY_ID="STD-Bassi-1984" TOTAL_1="19" TOTAL_2="19" VAR="0.7094594594594595" WEIGHT="0.8996606303142621"/>
<DICH_DATA CI_END="5.057289137848246" CI_START="0.04849784079915892" EFFECT_SIZE="0.49524499339486505" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7039177840423391" LOG_CI_START="-1.3142775964469091" LOG_EFFECT_SIZE="-0.305179906202285" ORDER="12527" O_E="-0.5" SE="1.1854979567276382" STUDY_ID="STD-Battistin-1985" TOTAL_1="20" TOTAL_2="20" VAR="0.7115384615384616" WEIGHT="0.9022969984617031"/>
<DICH_DATA CI_END="1.487985127506384" CI_START="0.13233219357866122" EFFECT_SIZE="0.443743547485869" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.17259859043419543" LOG_CI_START="-0.8783344884449336" LOG_EFFECT_SIZE="-0.3528679490053691" ORDER="12528" O_E="-2.132075471698113" SE="0.6173232927362409" STUDY_ID="STD-Hoffbrand-1988" TOTAL_1="27" TOTAL_2="26" VAR="2.6240655037379845" WEIGHT="3.3275593039206317"/>
<DICH_DATA CI_END="2.4399009085816066" CI_START="0.26580415325384926" EFFECT_SIZE="0.805317201498162" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3873721887444322" LOG_CI_START="-0.5754382373844955" LOG_EFFECT_SIZE="-0.09403302432003176" ORDER="12529" O_E="-0.6769230769230763" SE="0.5655596102966064" STUDY_ID="STD-Wender-1993" TOTAL_1="37" TOTAL_2="28" VAR="3.1263905325443786" WEIGHT="3.964554196317883"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Ganglioside versus control. Sensitivity analysis</NAME>
<DICH_OUTCOME CHI2="4.427694026982192" CI_END="1.0956446094317311" CI_START="0.7201694823918476" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.888284757980158" ESTIMABLE="YES" EVENTS_1="209" EVENTS_2="227" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.039669706345373326" LOG_CI_START="-0.14256528606058558" LOG_EFFECT_SIZE="-0.0514477898576061" METHOD="PETO" NO="1" P_CHI2="0.9744255139222939" P_Q="1.0" P_Z="0.26844226974522356" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1140" TOTAL_2="1125" WEIGHT="99.99999999999999" Z="1.1066570023002433">
<NAME>Case fatality at the end of scheduled follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.8562970727194978" CI_START="0.33092817941678887" EFFECT_SIZE="0.7837735710852834" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.26864747981313547" LOG_CI_START="-0.48026624993249006" LOG_EFFECT_SIZE="-0.10580938505967732" ORDER="12530" O_E="-1.2589285714285712" SE="0.43991563203533135" STUDY_ID="STD-Angeleri-1992" TOTAL_1="55" TOTAL_2="57" VAR="5.167270666712631" WEIGHT="5.921066803690585"/>
<DICH_DATA CI_END="1.7271775454183662" CI_START="0.5309597745983308" EFFECT_SIZE="0.9576334372851827" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="30" LOG_CI_END="0.23733698321438204" LOG_CI_START="-0.27493837973154384" LOG_EFFECT_SIZE="-0.018800698258580887" ORDER="12531" O_E="-0.47808764940239" SE="0.3009130839983804" STUDY_ID="STD-Argentino-1989" TOTAL_1="121" TOTAL_2="130" VAR="11.043782797098457" WEIGHT="12.654838487233716"/>
<DICH_DATA CI_END="1.4648532443900233" CI_START="0.3995663746157907" EFFECT_SIZE="0.7650530048337176" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="24" LOG_CI_END="0.16579411728799023" LOG_CI_START="-0.3984110668255989" LOG_EFFECT_SIZE="-0.11630847476880435" ORDER="12542" O_E="-2.4382470119521926" SE="0.33141691800902634" STUDY_ID="STD-Argentino-plus-haemo" TOTAL_1="128" TOTAL_2="123" VAR="9.10438577165442" WEIGHT="10.432524215889668"/>
<DICH_DATA CI_END="4.660501214038062" CI_START="0.2145691963319019" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6684326254422859" LOG_CI_START="-0.6684326254422859" LOG_EFFECT_SIZE="0.0" ORDER="12532" O_E="0.0" SE="0.7852812659593164" STUDY_ID="STD-Bassi-1984" TOTAL_1="19" TOTAL_2="19" VAR="1.6216216216216217" WEIGHT="1.8581821180347051"/>
<DICH_DATA CI_END="2.5837269275507135" CI_START="0.0838568025118707" EFFECT_SIZE="0.4654708140240617" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4122466114419634" LOG_CI_START="-1.0764617014116427" LOG_EFFECT_SIZE="-0.33210754498483963" ORDER="12533" O_E="-1.0" SE="0.8744746321952062" STUDY_ID="STD-Battistin-1985" TOTAL_1="20" TOTAL_2="20" VAR="1.3076923076923077" WEIGHT="1.4984571182613198"/>
<DICH_DATA CI_END="1.3914720481551834" CI_START="0.7052680198176271" EFFECT_SIZE="0.9906365307386883" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="84" LOG_CI_END="0.14347448666439214" LOG_CI_START="-0.15164580867152228" LOG_EFFECT_SIZE="-0.004085661003565066" ORDER="12534" O_E="-0.313043478260866" SE="0.17335512234933867" STUDY_ID="STD-EST-1994" TOTAL_1="404" TOTAL_2="401" VAR="33.275657252489914" WEIGHT="38.129875951330966"/>
<DICH_DATA CI_END="2.4816753242139535" CI_START="0.1295680244175102" EFFECT_SIZE="0.5670500586404044" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3947449624464862" LOG_CI_START="-0.8875021630674835" LOG_EFFECT_SIZE="-0.24637860031049863" ORDER="12535" O_E="-1.0" SE="0.7531983087525438" STUDY_ID="STD-Giraldi-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.7627118644067796" WEIGHT="2.019854460507781"/>
<DICH_DATA CI_END="2.352215231312953" CI_START="0.0642678182243554" EFFECT_SIZE="0.3888081029384302" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.37147705783561485" LOG_CI_START="-1.1920064433478315" LOG_EFFECT_SIZE="-0.4102646927561083" ORDER="12541" O_E="-1.12" SE="0.9183979479633062" STUDY_ID="STD-Heiss-1989" TOTAL_1="13" TOTAL_2="12" VAR="1.1856000000000002" WEIGHT="1.3585541101375338"/>
<DICH_DATA CI_END="1.5064374832316325" CI_START="0.15833818450722248" EFFECT_SIZE="0.4883918264759619" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.1779511132739668" LOG_CI_START="-0.8004143389530541" LOG_EFFECT_SIZE="-0.3112316128395437" ORDER="12536" O_E="-2.1698113207547163" SE="0.5746967096252473" STUDY_ID="STD-Hoffbrand-1988" TOTAL_1="27" TOTAL_2="26" VAR="3.027767888928444" WEIGHT="3.4694555584060227"/>
<DICH_DATA CI_END="2.220082799208475" CI_START="0.2900688168348892" EFFECT_SIZE="0.8024816451744498" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.34636917200414247" LOG_CI_START="-0.5374989564936012" LOG_EFFECT_SIZE="-0.09556489224472933" ORDER="12537" O_E="-0.816326530612244" SE="0.5191885138973733" STUDY_ID="STD-Kirczynska-1994" TOTAL_1="48" TOTAL_2="50" VAR="3.7097944584945273" WEIGHT="4.250975463354576"/>
<DICH_DATA CI_END="3.142214657862137" CI_START="0.5484364201472497" EFFECT_SIZE="1.3127471037073841" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4972358501949363" LOG_CI_START="-0.26087371262835807" LOG_EFFECT_SIZE="0.11818106878328911" ORDER="12538" O_E="1.3722222222222218" SE="0.4453173099052619" STUDY_ID="STD-Monaco-1991" TOTAL_1="91" TOTAL_2="89" VAR="5.042673460238636" WEIGHT="5.778293484723902"/>
<DICH_DATA CI_END="1.9002349154217466" CI_START="0.4708532598876954" EFFECT_SIZE="0.9459026400633146" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.27880729367118934" LOG_CI_START="-0.3271144184558366" LOG_EFFECT_SIZE="-0.024153562392323656" ORDER="12539" O_E="-0.43902439024390105" SE="0.3559214130642631" STUDY_ID="STD-SASS-1994" TOTAL_1="147" TOTAL_2="140" VAR="7.893902647025788" WEIGHT="9.045457056462922"/>
<DICH_DATA CI_END="2.4399009085816066" CI_START="0.26580415325384926" EFFECT_SIZE="0.805317201498162" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.3873721887444322" LOG_CI_START="-0.5754382373844955" LOG_EFFECT_SIZE="-0.09403302432003176" ORDER="12540" O_E="-0.6769230769230763" SE="0.5655596102966064" STUDY_ID="STD-Wender-1993" TOTAL_1="37" TOTAL_2="28" VAR="3.1263905325443786" WEIGHT="3.5824651719662937"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Ganglioside versus control. Disability assessment</NAME>
<CONT_OUTCOME CHI2="21.13912487680972" CI_END="8.856903586697571" CI_START="-4.757803861990276" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="2.0495498623536483" ESTIMABLE="YES" I2="90.53887040426133" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="2.568625197174601E-5" P_Q="1.0" P_Z="0.5551212008806666" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="64" UNITS="" WEIGHT="100.0" Z="0.5901035964043913">
<NAME>Mean Barthel index at the end of scheduled follow-up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="16.93580249326464" CI_START="0.4641975067353652" EFFECT_SIZE="8.700000000000003" ESTIMABLE="YES" MEAN_1="93.8" MEAN_2="85.1" ORDER="12543" SD_1="16.1" SD_2="22.1" SE="4.202017260637234" STUDY_ID="STD-Angeleri-1992" TOTAL_1="43" TOTAL_2="42" WEIGHT="68.31951741511793"/>
<CONT_DATA CI_END="-18.941776951613104" CI_START="-54.81822304838688" EFFECT_SIZE="-36.879999999999995" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="86.88" ORDER="12545" SD_1="25.63" SD_2="13.87" SE="9.152322792602979" STUDY_ID="STD-Heiss-1989" TOTAL_1="11" TOTAL_2="8" WEIGHT="14.401170640465715"/>
<CONT_DATA CI_END="24.576273977154166" CI_START="-8.17627397715416" EFFECT_SIZE="8.200000000000003" ESTIMABLE="YES" MEAN_1="88.2" MEAN_2="80.0" ORDER="12544" SD_1="16.2" SD_2="28.0" SE="8.355395357429076" STUDY_ID="STD-Hoffbrand-1988" TOTAL_1="19" TOTAL_2="14" WEIGHT="17.279311944416353"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2008-08-21 13:47:06 +0100" MODIFIED_BY="Hazel Fraser"/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>